<DOC>
	<DOCNO>NCT02952989</DOCNO>
	<brief_summary>This study examine safety profile SGN-2FF . The study test increase dos SGN-2FF give daily small group patient .</brief_summary>
	<brief_title>A Safety Study SGN-2FF Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study examine safety profile SGN-2FF give orally patient advance solid tumor . Patients may continue treatment progression disease intolerable side effect . The primary goal study identify optimal biological dose exceed maximum tolerate dose ( MTD ) . The pharmacokinetics ( PK ) antitumor activity SGN-2FF also evaluate study .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients histologically cytologicallyconfirmed , locally advanced , metastatic solid malignancy relapse , refractory , progress follow least 1 prior systemic therapy Measurable disease compute tomography ( CT ) magnetic resonance imaging ( MRI ) Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 1 Patients Part B must histologically cytologicallyconfirmed nonsmall cell lung cancer document Stage IIIB IV , recurrent disease follow radiation therapy surgical resection Adequate baseline hematologic , renal , hepatic function Patients carcinomatous meningitis active central nervous system ( CNS ) metastases Patients recent serious ongoing infection Patients require systemic treatment corticosteroid ( great 10 prednisone equivalent ) immunosuppressive medication within 14 day enrollment Patients active know suspected autoimmune disease significant autoimmunerelated toxicity prior immunooncology therapy Known active latent tuberculosis Uncontrolled diabetes mellitus History interstitial lung disease Gastrointestinal abnormality would affect absorption SGN2FF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>